Project Details
Description
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Obesity and Heart Failure
| Status | Active |
|---|---|
| Effective start/end date | 12/1/25 → 5/26/36 |
Funding
- AMGEN INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.